Selexis to Meet with Companies Interested in Mammalian Cell Line Development, Lead Identification for Therapeutic Drug Development and Solutions for Difficult-to-Express Proteins
Geneva, Switzerland (PRWEB) May 30 2012 – Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today that representatives from the Company will be participating in the 2012 BIO International Convention’s One-on-One Partnering Meetings being held June 18-21 in Boston, MA at the Boston Convention & Exhibition Center.
Selexis has developed a suite of services and technologies within the SUREtechnology Platform™ that speed and boost the productivity of manufacturing cell lines, improve outcomes in biologics drug discovery and lead identification and overcome bottlenecks in difficult-to-express proteins. Selexis has interactive collaborations, partnerships and commercial deals with leading biotechnology and pharmaceutical companies worldwide in a wide range of areas including bio-manufacturing, drug discovery, diagnostics, and therapeutics.
Representatives available to discuss Selexis’ capabilities include Dr. Igor Fisch, CEO; Dr. Armelle Gaussin, Chief Technology Officer; Andrew Sandford, VP Business Development and Licensing; and Yemi Onakunle VP Strategic and Market Development. Companies or individuals attending BIO 2012 can schedule meetings with Selexis by visiting (registration required): http://oneononepartnering.bio.org/BusinessForum2012/
Selexis Partnering Schedule:
Monday, June 18 Business Forum - 8:00 AM – 5:00 PM
Tuesday, June 19 Business Forum - 8:00 AM – 5:00 PM
Wednesday, June 20 Business Forum - 8:00 AM – 5:00 PM
Thursday, June 21 Business Forum - 8:00 AM – 12:00 PM
For companies or individuals not participating in partnering meetings, Selexis will be exhibiting in booth number #1102 located in Hall A – Discovery Zone (http://www.mapyourshow.com/shows/index.cfm?show_id=bio12).